Matica Biotechnology, the U.S. subsidiary of South Korea’s CHA Biotech, Tuesday announced the signing of a joint research agreement with Sartorius, a pharmaceutical and lab equipment supplier in Germany, to develop the process technology of viral vectors to be used for various gene and cell therapies.

Under the agreement, Matica will use Sartorius’ single-use platform that utilizes disposable bioreactors designed to reduce the risk of cross-contamination between batches while providing space, time and cost flexibility. The two will cooperate to develop real-time process analytical technology (PAT) and automation software needed for large-scale vector production with superiority in turnaround time and quality.

The real-time PAT ensures that major process variables in viral vector production such as dissolved oxygen and hydrogen ion levels are maintained at target values, while the automation software analyzes collected data in real time.

Satorius, the largest player in the single-use platform market, is a global provider of advanced equipment and technical services for biopharmaceutical process, R&D, and quality assurance, among others. Matica specializes in the clinical and commercial production of viral vectors for cell and gene therapies.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]